The European Commission approved olaparib as monotherapy or in combination with endocrine therapy for patients with germline BRCA1/2-mutant, HER2-negative high-risk early breast cancer.
Focusing on breast cancer, lung cancer, and GI cancers respectively, expert oncologists review the utility of circulating tumor DNA assays.
Expert panelists elucidate the mechanisms of ctDNA and MRD testing, providing a broad perspective on how they are used in cancer care.
Treatment with adjuvant radiotherapy in the prone position lowered the odds of desquamation in patients with breast cancer and large breast size.
Mark Pegram, MD, spoke the most important data from the IDEAL trial he believes his colleagues should take away.
Valentina Boni, MD, PhD, spoke about the safety profile observed of lurbinectedin monotherapy and future analyses for patients with BRCA1/2-associated metastatic breast cancer.
Hope S. Rugo, MD, FASCO, gave an overview of ribociclib plus aromatase inhibitor use vs abemaciclib plus aromatase inhibitors for patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Findings from the phase 1/2 FAKTION trial indicated that survival had increased following the addition of capivasertib to fulvestrant for patients with aromatase inhibitor–resistant, estrogen receptor–positive, HER2-negative advanced breast cancer.
Hope S. Rugo, MD, FASCO, reviewed data from a matching-adjusted indirect comparison study which analyzed quality of life in patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with ribociclib- or abemaciclib-based regimens.
Investigators reported a reduction in racial and ethnic disparities among patients with de novo stage IV breast cancer following implementation of Medicaid expansion, and included a decreased risk of death for patients in a racial/ethnic minority compared with White patients.